Human FGFR1/SRE-Luc Reporter Cell Line - HEK293

The Human FGFR1/SRE-Luc Reporter Cell Line - HEK293 is an advanced in vitro assay system built upon the highly characterized Human Embryonic Kidney 293 (HEK293) lineage. HEK293 cells are widely utilized in molecular biology due to their stable adherent growth, classic epithelial morphology, and exceptional amenability to complex genetic modifications. This specific reporter line is precisely engineered to stably overexpress the human Fibroblast Growth Factor Receptor 1 (FGFR1)—a vital receptor tyrosine kinase—alongside a stably integrated firefly luciferase (Luc) reporter gene. This reporter is strategically placed under the transcriptional control of a promoter containing multiple Serum Response Elements (SRE). Biologically, when a specific FGF ligand binds to the FGFR1 receptor, it induces receptor dimerization and autophosphorylation. This event rapidly activates the downstream MAPK/ERK intracellular signaling cascade, culminating in the activation of specific transcription factors (such as Elk-1 and SRF) that bind directly to the engineered SRE promoter. Consequently, this initiates the transcription of the luciferase enzyme, generating a robust, quantifiable bioluminescent signal that accurately reflects the functional activation status of the FGFR1 signaling axis.

The highly responsive nature of this engineered cell line makes it an essential tool for fundamental signal transduction research and targeted oncological drug discovery. In laboratory settings, the dynamic bioluminescent output serves as a highly sensitive, real-time metric for quantifying FGFR1/MAPK pathway activation. This provides an optimal platform for the high-throughput screening (HTS) and characterization of novel pharmacological agents, particularly small-molecule tyrosine kinase inhibitors (TKIs), recombinant neutralizing antibodies, and selective pathway modulators. Because aberrant FGFR1 signaling, gene amplification, and structural alterations are major drivers in several severe pathologies—most notably squamous cell lung cancer, hormone-receptor-positive breast cancer, and various developmental skeletal dysplasias—accurately monitoring its activity is paramount for therapeutic development.